The DOI matches its Crossref record; 36 of the 37 references it cites were found in a registry or an index.
Non-invasive stratification of hepatocellular carcinoma risk in non-alcoholic fatty liver using polygenic risk scores
Open accessAbstract
Background & Aims Hepatocellular carcinoma (HCC) risk stratification in individuals with dysmetabolism is a major unmet need. Genetic predisposition contributes to non-alcoholic fatty liver disease (NAFLD). We aimed to exploit robust polygenic risk scores (PRS) that can be evaluated in the clinic to gain insight into the causal relationship between NAFLD and HCC, and to improve HCC risk stratification. Methods We examined at-risk individuals (NAFLD cohort, n = 2,566; 226 with HCC; and a replication cohort of 427 German patients with NAFLD) and the general population (UK Biobank [UKBB] cohort, n = 364,048; 202 with HCC). Variants in PNPLA3-TM6SF2-GCKR-MBOAT7 were combined in a hepatic fat PRS (PRS-HFC), and then adjusted for HSD17B13 (PRS-5). Results In the NAFLD cohort, the adjusted impact of genetic risk variants on HCC was proportional to the predisposition to fatty liver ( p = 0.002) with some heterogeneity in the effect. PRS predicted HCC more robustly than single variants ( p < 10 -13 ). The association between PRS and HCC was mainly mediated through severe fibrosis, but was independent of fibrosis in clinically relevant subgroups, and was also observed in those without severe fibrosis ( p < 0.05). In the UKBB cohort, PRS predicted HCC independently of classical risk factors and cirrhosis ( p < 10 -7 ). In the NAFLD cohort, we identified high PRS cut-offs (≥0.532/0.495 for PRS-HFC/PRS-5) that in the UKBB cohort detected HCC with ~90% specificity but limited sensitivity; PRS predicted HCC both in individuals with ( p < 10 -5 ) and without cirrhosis ( p < 0.05). Conclusions Our results are consistent with a causal relationship between hepatic fat and HCC. PRS improved the accuracy of HCC detection and may help stratify HCC risk in individuals with dysmetabolism, including those without severe liver fibrosis. Further studies are needed to validate our findings. Lay summary By analyzing variations in genes that contribute to fatty liver disease, we developed two risk scores to help predict liver cancer in individuals with obesity-related metabolic complications. These risk scores can be easily tested in the clinic. We showed that the risk scores helped to identify the risk of liver cancer both in high-risk individuals and in the general population.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Comprehensive polygenic risk scores are superior to PNPLA3 and TM6SF2 alone for risk prediction of progressive MASLD, especially in individuals with metabolic triggers, and the bene fi ts of their use over clinical risk factors alone becomes more evident for long-term prediction. 196,206,207”
From EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). (2024) · cites this paper as [206]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Another model incorporated genetic variants in a risk score that predicted HCC independently of classical risk factors, but the AUROC when used alone was only 0.65. 206”
From EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). (2024) · cites this paper as [206]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008
Ferlay, J., Shin, H., Bray, F., Forman, D., Mathers, C. D., & Parkin, D. M. (2010) · International Journal of Cancer · doi:10.1002/ijc.25516 · Cited by 21,468
A global reference for human genetic variation
The 1000 Genomes Project Consortium, authors, C., Auton, A., Abecasis, G. R., Steering committee, Altshuler, D. M., Durbin, R. M., Abecasis, G. R., Bentley, D. R., Chakravarti, A., et al. (2015) · Nature · doi:10.1038/nature15393 · Cited by 18,247
Sudlow, C., Gallacher, J., Allen, N., Beral, V., Burton, P., Danesh, J., Downey, P., Elliott, P., Green, J., Landray, M., et al. (2015) · PLOS Medicine · doi:10.1371/journal.pmed.1001779 · Cited by 12,728
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
Galle, P. R., Forner, A., Llovet, J. M., Mazzaferro, V., Piscaglia, F., Raoul, J.-L., Schirmacher, P., & Vilgrain, V. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.03.019 · Cited by 11,406
The UK Biobank resource with deep phenotyping and genomic data
Bycroft, C., Freeman, C., Petkova, D., Band, G., Elliott, L. T., Sharp, K., Motyer, A., Vukcevic, D., Delaneau, O., O’Connell, J., et al. (2018) · Nature · doi:10.1038/s41586-018-0579-z · Cited by 8,876
EASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma
European Association for the Study of the Liver, & European Organisation for Research and Treatment of Cancer (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2011.12.001 · Cited by 5,218
EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease
(2016) · Journal of Hepatology · doi:10.1016/j.jhep.2015.11.004 · Cited by 4,836
Mendelian randomization: Using genes as instruments for making causal inferences in epidemiology
Lawlor, D. A., Harbord, R. M., Sterne, J. A. C., Timpson, N., & Davey Smith, G. (2008) · Statistics in Medicine · doi:10.1002/sim.3034 · Cited by 4,618
Eslam, M., Newsome, P. N., Sarin, S. K., Anstee, Q. M., Targher, G., Romero-Gomez, M., Zelber-Sagi, S., Wai-Sun Wong, V., Dufour, J.-F., Schattenberg, J. M., et al. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.03.039 · Cited by 4,472
Reading Mendelian randomisation studies: a guide, glossary, and checklist for clinicians
Davies, N. M., Holmes, M. V., & Davey Smith, G. (2018) · BMJ · doi:10.1136/bmj.k601 · Cited by 4,404
Flagged first, then by citations
1 of the 37 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Tacke, F., Horn, P., Wai-Sun Wong, V., Ratziu, V., Bugianesi, E., Francque, S., Zelber-Sagi, S., Valenti, L., Roden, M., Schick, F., et al. (2024) · Journal of Hepatology · doi:10.1016/j.jhep.2024.04.031 · Cited by 2,210
Global Epidemiology and Genetics of Hepatocellular Carcinoma
Toh, M. R., Wong, E. Y. T., Wong, S. H., Ng, A. W. T., Loo, L., Chow, P. K.-H., & Ngeow, J. Y. Y. (2023) · Gastroenterology · doi:10.1053/j.gastro.2023.01.033 · Cited by 622
(2024) · Obesity Facts · doi:10.1159/000539371 · Cited by 545
Nonalcoholic steatohepatitis-related hepatocellular carcinoma: pathogenesis and treatment
Llovet, J. M., Willoughby, C. E., Singal, A. G., Greten, T. F., Heikenwälder, M., El-Serag, H. B., Finn, R. S., & Friedman, S. L. (2023) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-023-00754-7 · Cited by 354
Epidemiology and risk-stratification of NAFLD-associated HCC
Ioannou, G. N. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2021.08.012 · Cited by 361
Metabolic Dysfunction–Associated Steatotic Liver Disease
Targher, G., Valenti, L., & Byrne, C. D. (2025) · New England Journal of Medicine · doi:10.1056/nejmra2412865 · Cited by 325
Non-Alcoholic Fatty Liver Disease: Metabolic, Genetic, Epigenetic and Environmental Risk Factors
Juanola, O., Martínez‐López, S., Francés, R., & Gómez‐Hurtado, I. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph18105227 · Cited by 330
Metabolic dysfunction-associated steatotic liver disease in adults
Huang, D. Q., Wong, V. W., Rinella, M. E., Boursier, J., Lazarus, J. V., Yki‐Järvinen, H., & Loomba, R. S. (2025) · Nature Reviews Disease Primers · doi:10.1038/s41572-025-00599-1 · Cited by 365
Long, M. T., Noureddin, M., & Lim, J. K. (2022) · Gastroenterology · doi:10.1053/j.gastro.2022.06.023 · Cited by 299
Biomarkers for diagnosis and therapeutic options in hepatocellular carcinoma
Chan, Y.-T., Zhang, C., Wu, J., Lu, P., Xu, L., Yuan, H., Feng, Y., Chen, Z.-S., & Wang, N. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02101-z · Cited by 313
NAFLD‐related hepatocellular carcinoma: The growing challenge
Shah, P. A., Patil, R., & Harrison, S. A. (2022) · Hepatology · doi:10.1002/hep.32542 · Cited by 270
Impact of non-invasive biomarkers on hepatology practice: past, present and future
Anstee, Q. M., Castera, L., & Loomba, R. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.03.026 · Cited by 224
Liver fibrosis in NAFLD/NASH: from pathophysiology towards diagnostic and therapeutic strategies
Parola, M., & Pinzani, M. (2023) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2023.101231 · Cited by 239
Chen, Y., Du, X., Kuppa, A., Feitosa, M. F., Bielak, L. F., O’Connell, J. R., Musani, S. K., Guo, X., Kahali, B., Chen, V. L., et al. (2023) · Nature Genetics · doi:10.1038/s41588-023-01497-6 · Cited by 215
The intersection between alcohol-related liver disease and nonalcoholic fatty liver disease
Díaz, L. A., Arab, J. P., Louvet, A., Bataller, R., & Arrese, M. (2023) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-023-00822-y · Cited by 207
Molecular mechanisms in MASLD/MASH-related HCC
Wang, X., Zhang, L., & Dong, B. (2024) · Hepatology · doi:10.1097/hep.0000000000000786 · Cited by 193
The first MASH drug therapy on the horizon: Current perspectives of resmetirom
Petta, S., Targher, G., Romeo, S., Pajvani, U. B., Zheng, M., Aghemo, A., & Valenti, L. V. C. (2024) · Liver International · doi:10.1111/liv.15930 · Cited by 182
Raverdy, V., Tavaglione, F., Chatelain, E., Lassailly, G., Vincentis, A. D., Gentilucci, U. V., Qadri, S. U., Caiazzo, R. J., Verkindt, H., Saponaro, C., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-03283-1 · Cited by 197
Asian perspective on NAFLD-associated HCC
Yip, T. C., Lee, H. W., Chan, W., Wong, G. L., & Wong, V. W. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2021.09.024 · Cited by 159
Mitochondria, oxidative stress and nonalcoholic fatty liver disease: A complex relationship
Karkucińska‐Więckowska, A., Simões, I. C. M., Kalinowski, P., Lebiedzińska, M., Zieniewicz, K., Milkiewicz, P., Górska‐Ponikowska, M., Pinton, P., Malik, A. N., Krawczyk, M. J., et al. (2021) · European Journal of Clinical Investigation · doi:10.1111/eci.13622 · Cited by 172
De Vincentis, A., Tavaglione, F., Jamialahmadi, O., Picardi, A., Antonelli Incalzi, R., Valenti, L., Romeo, S., & Vespasiani-Gentilucci, U. (2022) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2021.05.056 · Cited by 158
Noninvasive assessment of liver fibrosis in NAFLD
Sanyal, A. J., Castera, L., & Wong, V. W.-S. (2023) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2023.03.042 · Cited by 157
Hepatocellular and extrahepatic cancer risk in people with non-alcoholic fatty liver disease
Thomas, J. A., Kendall, B. J., El‐Serag, H. B., Thrift, A. P., & Macdonald, G. A. (2024) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(23)00275-3 · Cited by 144
Risk stratification and early detection biomarkers for precision HCC screening
Lee, Y., Fujiwara, N., Yang, J. D., & Hoshida, Y. (2022) · Hepatology · doi:10.1002/hep.32779 · Cited by 128
Development and Validation of a Score for Fibrotic Nonalcoholic Steatohepatitis
Tavaglione, F., Jamialahmadi, O., Vincentis, A. D., Qadri, S. U., Mowlaei, M. E., Mancina, R. M., Ciociola, E., Carotti, S., Perrone, G., Bruni, V., et al. (2022) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2022.03.044 · Cited by 121
Longo, M., Meroni, M., Paolini, E., Erconi, V., Carli, F., Fortunato, F., Ronchi, D., Piciotti, R., Sabatini, S., Macchi, C., et al. (2021) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2021.11.007 · Cited by 116
Metabolic dysfunction–associated fatty liver disease and the risk of 24 specific cancers
Liu, Z., Lin, C., Suo, C., Zhao, R., Li, J., Zhang, T., & Chen, X. (2021) · Metabolism · doi:10.1016/j.metabol.2021.154955 · Cited by 117
Chen, V. L., Oliveri, A., Miller, M. J., Wijarnpreecha, K., Du, X., Chen, Y., Cushing, K. C., Lok, A. S., & Speliotes, E. K. (2023) · Gastroenterology · doi:10.1053/j.gastro.2023.01.040 · Cited by 108
Emerging Evidence of Pathological Roles of Very-Low-Density Lipoprotein (VLDL)
Huang, J.-K., & Lee, H. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23084300 · Cited by 115
Insights into Nonalcoholic Fatty-Liver Disease Heterogeneity
Arrese, M. A., Arab, J. P., Francisco Barrera, M., Kaufmann, B. K., Valenti, L. V. C., & Feldstein, A. E. (2021) · Seminars in Liver Disease · doi:10.1055/s-0041-1730927 · Cited by 109
Roeb, E., Canbay, A. E., Tacke, F., Bantel, H., Bojunga, J., de Laffolie, J., Demir, M., Denzer, U. W., Geier, A., Hofmann, W. P., et al. (2022) · Zeitschrift für Gastroenterologie · doi:10.1055/a-1880-2283 · Cited by 108
Rare ATG7 genetic variants predispose patients to severe fatty liver disease
Baselli, G. A., Jamialahmadi, O., Pelusi, S., Ciociola, E., Malvestiti, F., Saracino, M., Santoro, L., Cherubini, A., Dongiovanni, P., Maggioni, M., et al. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.03.031 · Cited by 97
Singal, A. G., Sanduzzi‐Zamparelli, M., Nahon, P., Ronot, M., Hoshida, Y., Rich, N. E., Reig, M., Vilgrain, V., Marrero, J. A., Llovet, J. M., et al. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.02.022 · Cited by 97
Perspectives on Precision Medicine Approaches to NAFLD Diagnosis and Management
Lonardo, A., Arab, J. P., & Arrese, M. A. (2021) · Advances in Therapy · doi:10.1007/s12325-021-01690-1 · Cited by 95
Le, M. H., Le, D. M., Baez, T. C., Dang, H., Nguyen, V. H., Lee, K., Stave, C. D., Ito, T., Wu, Y., Yeo, Y. H., et al. (2024) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2023.0485 · Cited by 92
Therapeutic opportunities for the treatment of NASH with genetically validated targets
Lindén, D., & Romeo, S. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.05.007 · Cited by 86
Kendall, T. J., Jimenez-Ramos, M., Turner, F., Ramachandran, P., Minnier, J., McColgan, M. D., Alam, M., Ellis, H., Dunbar, D. R., Kohnen, G., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02602-2 · Cited by 92
A genetic risk score and diabetes predict development of alcohol-related cirrhosis in drinkers
Whitfield, J. B., Schwantes-An, T.-H. L., Darlay, R., Aithal, G. P., Atkinson, S. R., Bataller, R. A., Botwin, G., Chalasani, N., Cordell, H. J., Daly, A. K., et al. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2021.10.005 · Cited by 90
Nahon, P., Bamba‐Funck, J., Layese, R., Trépo, E., Zucman‐Rossi, J., Cagnot, C., Ganne‐Carrié, N., Chaffaut, C., Guyot, E., Ziol, M., et al. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.11.003 · Cited by 84
Romeo, S., Vidal‐Puig, A., Husain, M., Ahima, R. S., Arca, M., Bhatt, D. L., Diehl, A. M., Fontana, L., Foo, R., Frühbeck, G., et al. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf314 · Cited by 93
Genetics of Metabolic Dysfunction-associated Steatotic Liver Disease: The State of the Art Update
Sookoian, S. C., Rotman, Y., & Valenti, L. V. C. (2024) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2024.05.052 · Cited by 88
Pοlyzos, S. A., Chrysavgis, L., Vachliotis, I. D., Chartampilas, E., & Cholongitas, Ε. (2023) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2023.04.010 · Cited by 84
Performance of routine risk scores for predicting cirrhosis-related morbidity in the community
Innes, H. A., Morling, J. R., Buch, S., Hamill, V., Stickel, F., & Guha, I. N. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.02.022 · Cited by 78
Tamaki, N., Ahlholm, N., Luukkonen, P. K., Porthan, K., Sharpton, S. R., Ajmera, V., Kono, Y., Dave, S., Ahmed, A., Sundaram, V., et al. (2022) · Journal of Clinical Investigation · doi:10.1172/jci162513 · Cited by 69
Genetics Is of the Essence to Face NAFLD
Meroni, M., Longo, M., Tria, G., & Dongiovanni, P. (2021) · Biomedicines · doi:10.3390/biomedicines9101359 · Cited by 69
Ahmed, A., Cule, M., Bell, J. D., Sattar, N. A., & Yaghootkar, H. (2024) · Journal of Hepatology · doi:10.1016/j.jhep.2024.06.030 · Cited by 66
Obesity Modifies the Performance of Fibrosis Biomarkers in Nonalcoholic Fatty Liver Disease
Qadri, S. U., Ahlholm, N., Lønsmann, I., Pellegrini, P., Poikola, A., Luukkonen, P. K., Porthan, K., Juuti, A., Sammalkorpi, H. E., Penttilä, A. K., et al. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab933 · Cited by 63
Gutiérrez‐Cuevas, J., Lucano‐Landeros, S., López-Cifuentes, D., Santos, A., & Armendáriz‐Borunda, J. (2022) · Cancers · doi:10.3390/cancers15010023 · Cited by 64
Remodeling of Mitochondrial Plasticity: The Key Switch from NAFLD/NASH to HCC
Longo, M., Paolini, E., Meroni, M., & Dongiovanni, P. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22084173 · Cited by 61
Amangurbanova, M., Huang, D. Q., & Loomba, R. S. (2022) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.17292 · Cited by 63
Talamantes, S., Lisjak, M., Gilglioni, E. H., Llamoza-Torres, C. J., Ramos‐Molina, B., & Gurzov, E. N. (2023) · JHEP Reports · doi:10.1016/j.jhepr.2023.100811 · Cited by 62
NAFLD-Associated HCC: Progress and Opportunities
Geh, D., Anstee, Q. M., & Reeves, H. L. (2021) · Journal of Hepatocellular Carcinoma · doi:10.2147/jhc.s272213 · Cited by 64
Motta, B. M., Masarone, M., Torre, P., & Persico, M. (2023) · Cancers · doi:10.3390/cancers15225458 · Cited by 61
Genetic predisposition similarities between NASH and ASH: Identification of new therapeutic targets
Bianco, C., Casirati, E., Malvestiti, F., & Valenti, L. V. C. (2021) · JHEP Reports · doi:10.1016/j.jhepr.2021.100284 · Cited by 51
Caviglia, G. P., Armandi, A., Rosso, C., Gaia, S., Aneli, S., Rolle, E., Abate, M. L., Olivero, A., Nicolosi, A., Guariglia, M., et al. (2021) · Cancers · doi:10.3390/cancers13102305 · Cited by 48
Hepatocellular Carcinoma in Metabolic Dysfunction-Associated Steatotic Liver Disease
Rodríguez, L. A., Schmittdiel, J. A., Liu, L., Macdonald, B. A., Balasubramanian, S., Chai, K. P., Seo, S., Mukhtar, N. A., Levin, T. R., & Saxena, V. (2024) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.21019 · Cited by 48
Caon, E., Martins, M. C., Hodgetts, H., Blanken, L., Vilia, M. G., Levi, A., Thanapirom, K., Al‐Akkad, W., Abu‐Hanna, J., Baselli, G., et al. (2024) · Journal of Hepatology · doi:10.1016/j.jhep.2024.01.032 · Cited by 45
Epidemiology, pathophysiology and clinical aspects of Hepatocellular Carcinoma in MAFLD patients
Argenziano, M. E., Kim, M. N., Montori, M., Bucchianico, A. D., Balducci, D., Ahn, S. H., & Svegliati‐Baroni, G. (2024) · Hepatology International · doi:10.1007/s12072-024-10692-4 · Cited by 52
Contribution of a genetic risk score to ethnic differences in fatty liver disease
Kubiliun, M. J., Cohen, J. C., Hobbs, H. H., & Kozlitina, J. (2022) · Liver International · doi:10.1111/liv.15322 · Cited by 45
MAFLD: an optimal framework for understanding liver cancer phenotypes
Crane, H., Gofton, C., Sharma, A., & George, J. (2023) · Journal of Gastroenterology · doi:10.1007/s00535-023-02021-7 · Cited by 46
Tesfai, K., Pace, J., El-Newihi, N., Martinez, M. E., Tincopa, M. A., & Loomba, R. S. (2024) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2024.06.038 · Cited by 49
Chen, V. L., Kuppa, A., Oliveri, A., Chen, Y., Ponnandy, P., Patel, P. B., Palmer, N. D., & Speliotes, E. K. (2025) · Journal of Clinical Investigation · doi:10.1172/jci186424 · Cited by 47
The contribution of genetics and epigenetics to MAFLD susceptibility
Moretti, V., Romeo, S., & Valenti, L. V. C. (2024) · Hepatology International · doi:10.1007/s12072-024-10667-5 · Cited by 48
Armandi, A., Rosso, C., Caviglia, G. P., & Bugianesi, E. (2024) · Metabolism · doi:10.1016/j.metabol.2024.156080 · Cited by 47
Carbone, F., Després, J., Ioannidis, J. P. A., Neeland, I. J., Garruti, G., Busetto, L., Liberale, L., Ministrini, S., Vilahur, G., Schindler, T. H., et al. (2025) · European Journal of Clinical Investigation · doi:10.1111/eci.70059 · Cited by 46
Chen, S., Pang, J., Huang, R., Xue, H., & Chen, X. (2023) · Hepatology International · doi:10.1007/s12072-023-10486-0 · Cited by 42
Insulin resistance is an integral feature of MASLD even in the presence of PNPLA3 variants
Bril, F., Kalavalapalli, S., Lomonaco, R., Frye, R. F., Leiva, E. G., & Cusi, K. J. (2024) · JHEP Reports · doi:10.1016/j.jhepr.2024.101092 · Cited by 41
Genetic Risk Factors for Metabolic Dysfunction-Associated Steatotic Liver Disease
Pei, Y., & Goh, G. B. (2025) · Gut and Liver · doi:10.5009/gnl240407 · Cited by 44
High inherited risk predicts age-associated increases in fibrosis in patients with MASLD
Díaz, L. A., Alazawi, W., Agrawal, S., Arab, J. P., Arrese, M. A., Idalsoaga, F. J., Barreyro, F. J., Gadano, A. C., Marciano, S., Morales, J. M., et al. (2025) · Journal of Hepatology · doi:10.1016/j.jhep.2025.04.035 · Cited by 49
Hepatocellular Carcinoma in Non-alcoholic Fatty Liver Disease: Current Progresses and Challenges
Teng, Y., Xie, S., Guo, P.-P., Deng, Z., Zhang, Z., Gao, W., Zhang, W., & Zhong, J. (2022) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2021.00586 · Cited by 41
Precision medicine and nucleotide-based therapeutics to treat steatotic liver disease
Caddeo, A. M., & Romeo, S. (2024) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2024.0438 · Cited by 42
Impact of PNPLA3 I148M on Clinical Outcomes in Patients With MASLD
Petta, S., Armandi, A., & Bugianesi, E. (2024) · Liver International · doi:10.1111/liv.16133 · Cited by 38
The burden of liver disease in Latin America
Díaz, L. A., Villota‐Rivas, M., Francisco Barrera, M., Lazarus, J. V., & Arrese, M. A. (2023) · Annals of Hepatology · doi:10.1016/j.aohep.2023.101175 · Cited by 42
Lin, H., Li, G., Delamarre, A., Ahn, S. H., Zhang, X., Kim, B. K., Liang, L. Y., Lee, H. W., Wong, G. L., Yuen, P. C., et al. (2023) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2023.11.005 · Cited by 37
Long‐term hepatic safety of lomitapide in homozygous familial hypercholesterolaemia
Larrey, D. G., D’Erasmo, L., O’Brien, S. L., Arca, M., & the Italian Working Group on Lomitapide (2022) · Liver International · doi:10.1111/liv.15497 · Cited by 35
Advances in the genetics of nonalcoholic fatty liver disease
Ajmera, V. H., & Loomba, R. S. (2023) · Current Opinion in Gastroenterology · doi:10.1097/mog.0000000000000927 · Cited by 36
A PDCD1 Role in the Genetic Predisposition to NAFLD-HCC?
Eldafashi, N., Darlay, R., Shukla, R., McCain, M. V., Watson, R., Liu, Y. L., McStraw, N. M., Fathy, M., Fawzy, M. A., Zaki, M. Y. W., et al. (2021) · Cancers · doi:10.3390/cancers13061412 · Cited by 37
Armandi, A., & Bugianesi, E. (2021) · Liver International · doi:10.1111/liv.14910 · Cited by 36
Seko, Y., Yamaguchi, K., Shima, T., Iwaki, M., Takahashi, H., Kawanaka, M., Tanaka, S., Mitsumoto, Y., Yoneda, M., Nakajima, A., et al. (2023) · Liver International · doi:10.1111/liv.15678 · Cited by 37
Guo, C., Liu, Z., Fan, H. X., Wang, H., Zhang, X., Zhao, S., Li, Y., Han, X., Wang, T., Chen, X., et al. (2024) · Hepatology · doi:10.1097/hep.0000000000000879 · Cited by 35
Teng, P., Huang, D. Q., Lin, T.-Y., Noureddin, M., & Yang, J. D. (2022) · Gut and Liver · doi:10.5009/gnl220357 · Cited by 34
Liu, Z., Huang, H., Xie, J., Xu, Y., & Xu, C. (2024) · Nature Communications · doi:10.1038/s41467-024-47960-8 · Cited by 32
Wang, Y., Song, S. J., Jiang, Y., Lai, J. C., Wong, G. L., Wong, V. W., & Yip, T. C. (2024) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2024.0246 · Cited by 32
Dallio, M., Romeo, M., Gravina, A. G., Masarone, M., Larussa, T., Abenavoli, L., Persico, M., Loguercio, C., & Federico, A. (2021) · Nutrients · doi:10.3390/nu13051679 · Cited by 32
The Emerging Factors and Treatment Options for NAFLD-Related Hepatocellular Carcinoma
Zhang, C., & Yang, M. J. (2021) · Cancers · doi:10.3390/cancers13153740 · Cited by 34
Varadharajan, V., Massey, W. J., & Brown, J. M. (2022) · Journal of Lipid Research · doi:10.1016/j.jlr.2022.100234 · Cited by 32
Deciphering the role of aberrant DNA methylation in NAFLD and NASH
Vachher, M., Bansal, S., Kumar, B., Yadav, S., & Burman, A. (2022) · Heliyon · doi:10.1016/j.heliyon.2022.e11119 · Cited by 33
Distinctive features of hepatocellular carcinoma in non-alcoholic fatty liver disease.
Valenti, L., Pedica, F., & Colombo, M. (2021) · Digestive and Liver Disease · doi:10.1016/j.dld.2021.06.023 · Cited by 25
NAFLD polygenic risk score and risk of hepatocellular carcinoma in an East Asian population
Thomas, C. E., Diergaarde, B. B., Kuipers, A. L., Adibi, J. J., Luu, H. N., Chang, X., Dorajoo, R., Heng, C., Khor, C. C., Wang, R., et al. (2022) · Hepatology Communications · doi:10.1002/hep4.1976 · Cited by 31
Yu, J., Li, D., You, Y., Yu, J., Jiang, W., Liu, Y., Zeng, R., Wan, Z., Yi, L., & Liao, X. (2023) · BMC Medicine · doi:10.1186/s12916-023-03080-6 · Cited by 31
Differences between hepatocellular carcinoma caused by alcohol and other aetiologies
Ganne‐Carrié, N., & Nahon, P. (2024) · Journal of Hepatology · doi:10.1016/j.jhep.2024.12.030 · Cited by 34
Bergamot Polyphenol Extract Reduces Hepatocyte Neutral Fat by Increasing Beta-Oxidation
Mirarchi, A., Mare, R., Musolino, V., Nucera, S., Mollace, V., Pujia, A., Montalcini, T., Romeo, S., & Maurotti, S. (2022) · Nutrients · doi:10.3390/nu14163434 · Cited by 30
Hepatocellular carcinoma surveillance in patients with non-alcoholic fatty liver disease
Dahan, K. S. E., Daher, D., & Singal, A. (2022) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2022.0247 · Cited by 25
Authors, & Collaborators: (2022) · Zeitschrift für Gastroenterologie · doi:10.1055/a-1880-2388 · Cited by 30
Männistö, V., Salomaa, V. V., Färkkilä, M. A., Jula, A., Männistö, S., Erlund, I., Sundvall, J., Lundqvist, A., Perola, M., & Åberg, F. O. (2021) · Liver International · doi:10.1111/liv.15004 · Cited by 29
Non-alcoholic steatohepatitis and risk of hepatocellular carcinoma
Rios, R. S., Zheng, K. I., & Zheng, M.-H. (2021) · Chinese Medical Journal · doi:10.1097/cm9.0000000000001888 · Cited by 29
Hepatocellular carcinoma in non-alcoholic steatohepatitis without cirrhosis
Tovo, C. V., de Mattos, Â. Z., Coral, G. P., SARTORI, G. D. P., Nogueira, L. V., Both, G. T., Villela‐Nogueira, C. A., & de Mattos, Â. A. (2023) · World Journal of Gastroenterology · doi:10.3748/wjg.v29.i2.343 · Cited by 35
Genetic Polymorphisms and Diversity in Nonalcoholic Fatty Liver Disease (NAFLD): A Mini Review
Sulaiman, S. A., Dorairaj, V., & Adrus, M. N. H. (2022) · Biomedicines · doi:10.3390/biomedicines11010106 · Cited by 30
Genetics, Immunity and Nutrition Boost the Switching from NASH to HCC
Dongiovanni, P., Meroni, M., Longo, M., Fargion, S. R., & Fracanzani, A. L. (2021) · Biomedicines · doi:10.3390/biomedicines9111524 · Cited by 27
Valenti, L. V. C., Tripodi, A., Mura, V. L., Pelusi, S., Bianco, C., Scalambrino, E., Margarita, S., Malvestiti, F., Ronzoni, L., Clerici, M., et al. (2022) · JHEP Reports · doi:10.1016/j.jhepr.2022.100598 · Cited by 27
Metadata
- Authors
- Bianco, C., Jamialahmadi, O., Pelusi, S., Baselli, G., Dongiovanni, P., Zanoni, I., Santoro, L., Maier, S., Liguori, A., Meroni, M., Borroni, V., D’Ambrosio, R., Spagnuolo, R., Alisi, A., Federico, A., Bugianesi, E., Petta, S., Miele, L., Vespasiani-Gentilucci, U., Anstee, Q. M., Stickel, F., Hampe, J., Fischer, J., Berg, T., Fracanzani, A. L., Soardo, G., Reeves, H., Prati, D., Romeo, S., & Valenti, L.
- Affiliations
- Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico (IT)
- Sahlgrenska University Hospital (SE)
- University of Milan (IT)
- University of Udine (IT)
- Agostino Gemelli University Polyclinic (IT)
- Bambino Gesù Children's Hospital (IT)
- University of Campania "Luigi Vanvitelli" (IT)
- Azienda Ospedaliera Citta' della Salute e della Scienza di Torino (IT)
- University of Palermo (IT)
- Newcastle upon Tyne Hospitals NHS Foundation Trust (GB)
- University Hospital Zurich (CH)
- University Hospital Carl Gustav Carus (DE)
- University Hospital Leipzig (DE)
- Corresponding author
- Romeo, Stefano
- Valenti, Luca
- ORCID
- Bianco, Cristiana
- Jamialahmadi, Oveis
- Pelusi, Serena
- Baselli, Guido
- Dongiovanni, Paola
- Maier, Silvia
- Liguori, Antonio
- Meroni, Marica
- Borroni, Vittorio
- D’Ambrosio, Roberta
- Spagnuolo, Rocco
- Alisi, Anna
- Federico, Alessandro
- Bugianesi, Elisabetta
- Petta, Salvatore
- Miele, Luca
- Anstee, Quentin M.
- Stickel, Felix
- Hampe, Jochen
- Fischer, Janett
- Berg, Thomas
- Fracanzani, Anna Ludovica
- Soardo, Giorgio
- Reeves, Helen
- Prati, Daniele
- Romeo, Stefano
- Valenti, Luca
- Venue
- Journal of Hepatology
- Publisher
- Elsevier BV
- Published
- 2021-04
- Volume
- 74
- Issue
- 4
- Pages
- 775-782
- ISSN
- 0168-8278 (ISSN-L)
- PMC
- PMC7987554
- OpenAlex
- W3106622583
- Cited by
- 385
- References
- 37
- Citations by year
- 2026: 60 · 2025: 60 · 2024: 68 · 2023: 80 · 2022: 64 · 2021: 52
- FWCI
- 35.27
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Journal of Hepatology (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion, other-oa)
- Institutional Research Information System (University of Udine) (submittedVersion, cc-by-nc-nd)
- Archivio Istituzionale della Ricerca - Università degli Studi della Campania "Luigi Vanvitelli" (submittedVersion)
- Nova Science Publishers (Nova Science Publishers, Inc.) (submittedVersion, other-oa)
- Newcastle University ePrints (Newcastle Univesity) (cc-by-nc-nd)
- Funders
- Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (310030_169196)
- Marianne and Marcus Wallenberg Foundation (KAW 2017.0203)
- Knut och Alice Wallenbergs Stiftelse
- Swiss Foundation for Alcohol Research
- AbbVie
- Akebia Therapeutics
- Amgen
- Novo Nordisk
- Novo Nordisk Fonden (DIA 2017-205, 9321-430)
- Hjärt-Lungfonden (20120533)
- European Research Council
- Seventh Framework Programme
- Diabetesförbundet
- Sanofi
- Pfizer
- Celgene
- Vetenskapsrådet (2016-01527)
- European Commission
- Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico (RC100017A)
- Associazione Italiana per la Ricerca sul Cancro (16888)
- Ministero della Salute (RF-2016-02364358)
- Cancer Research UK (C18342/A23390, C9380/A18084, C9380/A26813)
- Gilead Sciences
- AstraZeneca
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
- Health Sciences › Medicine › Hepatology › Hepatocellular Carcinoma Treatment and Prognosis
- Keywords
- hepatocellular carcinoma, non-alcoholic fatty liver disease, polygenic risk score, HCC risk stratification, hepatic steatosis, liver fibrosis, PNPLA3, TM6SF2, GCKR, MBOAT7, HSD17B13, genetic susceptibility, liver cirrhosis, HCC detection, UK Biobank
- MeSH terms
- Mediation Analysis, Cross-Sectional Studies, Europe, Female, Carcinoma, Hepatocellular, Humans, Liver, Liver Cirrhosis, Liver Neoplasms, Male, Middle Aged, Predictive Value of Tests, Prognosis, Risk Factors, Risk Assessment, Genetic Predisposition to Disease, Multifactorial Inheritance, Adiposity, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
